68 results about "Pattern recognition receptor" patented technology

This invention relates to a vaccine and a method for immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from a disease including cancer, a disease associated with allergic inflammation, an infectious disease, or a condition associated with a deleterious activity of a self-antigen. Also disclosed are therapeutic compositions useful in such a method.

The invention refers to a method for the prognosis of a disease in a subject by the administration of a biopharmaceutical treatment in a subject suffering from, or likely to suffer from the disease, the method involving the analysis of SNP polymorphisms in the subjects pattern recognition receptor genes (PRRs), eg the analysis of polymorphisms' with the purpose of predicting the response of anti-TNFx antibody therapy in rheumatoid arthritis patients. Also the response to Beta-interferon in multiple sclerosis patients may be predicted. The genes whose polymorphisms are analysed may be TLRs, NOD-like receptors or retinoic acid-inducible gene I-like receptors (RLR).

The present invention relates, in general, to pattern-recognition receptors (PRRs), including toll-like receptors (TLRs), and, in particular, to a method of inhibiting nucleic acid-induced activation of, for example, endosomal TLRs using an agent that binds to the nucleic acid (“nucleic acid binding agent”), preferably, in a manner that is independent of the nucleotide sequence, the chemistry (e.g., DNA or RNA, with or without base or sugar modifications) and / or the structure (e.g., double-stranded or single-stranded, complexed or uncomplexed with, for example protein) of the nucleic acid(s) responsible for inducing TLR activation. The invention also relates to methods of identifying nucleic acid binding agents suitable for use in such methods.

The invention relates to the technical field of biomedical engineering, and provides a composition and a method related to soluble dimeric immune fusion protein. The dimeric immune fusion protein comprises a first dimerized polypeptide chain and a second dimerized polypeptide chain. The general structural formula of the first polypeptide chain is Z1-Z2, and the general structural formula of the second polypeptide chain is Y1-Y2. Z1 is (i) an extracellular domain of a first pattern recognition receptor or a functional variant or fragment thereof, or (ii) a functional variant or fragment thereofof a first co-receptor; and Z2 is a dimerized domain or a functional variant or fragment thereof. Y1 is (i) an extracellular domain of a second pattern recognition receptor or a functional variant orfragment thereof, or (ii) a second co-receptor or a functional variant or fragment thereof; and Y2 is a dimerized domain or a functional variant or fragment thereof. The dimeric protein provided by the invention can be used for blocking pathogen invasion and limiting generation and expansion of inflammatory mediators, and can be used for preparing products for preventing or treating inflammatorymediator-related diseases.

A method for conducting a neutralization assay for the determination of the titer of antibodies in a sample is provided which is an improvement over existing neutralization assays because the sensitivity of the reporter gene assay to determine neutralization is increased by the use of a “one time use” cell line transformed with a reporter gene construct. The titer is determined for antibodies specific for a predetermined target molecule that activates the signal transduction activity of a cell surface protein or a pattern recognition receptor or are specific for an antagonist for the predetermined target molecule.

The invention discloses protein BxCDP1 of bursaphelenchus-xylophilus pathogen-associated molecular patterns and application thereof. The amino acid sequence of the protein BxCDP1 of the pathogen-associated molecular patterns (PAMPS) is shown in SEQID NO.2. From effectors secreted by bursaphelenchus xylophilus and the PAMP, the defensive responses of a host plant, namely, a pine tree, to bursaphelenchus xylophilus invasion are studied, the protein BxCDP1 of the pathogen-associated molecular patterns is obtained from the bursaphelenchus xylophilus, it is proven through experiments that the protein BxCDP1 can trigger cell necrosis of various plants including the host plant, has a certain broad spectrum in cell necrosis triggering, and stimulates the defensive response of the host plant. The BxCDP1 triggered cell necrosis depends on a co-receptor BAK1 of pattern recognition receptors, the BxCDP1 can stimulate the accumulation of nicotiana benthamiana ROS and up regulation of PTI Marker genes, and the immunoreaction of the nicotiana benthamiana is stimulated. It can be seen that the BxCDP1 is a PAMP secreted by the bursaphelenchus xylophilus, and has important theoretical and practicalsignificance for revealing the pathogenic mechanism of the bursaphelenchus xylophilus and improving the resistance of the pine tree to the bursaphelenchus xylophilus in a targeted mode.

Provided are methods for activating an antigen-presenting cell and eliciting an immune response by inducing an inducible pattern recognition receptor adapter, or adapter fragment, and CD40 activity. Also provided are nucleic acid compositions comprising sequences coding for chimeric proteins that include an inducible CD40 peptide and an inducible pattern recognition receptor adapter or adapter fragment.

The disclosure herein relates to the novel finding that pattern recognition receptor activation is central to pancreatic cancer progression, and provides antagonists of pattern recognition receptors (PRRs), including the TLRs 4, 7, and 9, and the CLR dectin-1, for treatment and prevention of pancreatic cancer and pancreatic inflammation. The inventors have discovered that cancer development and progression can be prevented by pattern recognition receptor inhibition, a powerful finding with important clinical and therapeutic implications.

The invention relates to the fields of biotechnology and medical diagnosis. The research finds that the molecular expression of a pattern recognition receptor RIG-I in the tumor tissue of a tumor patient is obviously decreased and the correlation exists between the decreasing amplitude and the survival time of the tumor patient; moreover, the low expression of the molecules of the pattern recognition receptor RIG-I is significantly correlated with the prognosis difference of the patient. The invention provides an application of the pattern recognition receptor RIG-I in preparation of a kit for tumor diagnosis or prognosis evaluation, and the corresponding detection kit.

The invention discloses a preparation method of a porcine TLR4 polyclonal antibody. According to the preparation method, recombinant TLR4 protein (antigen) and freund's adjuvant are emulsified, then an immune animal obtains polyclonal antibody serum, wherein the recombinant TLR4 protein has the amino acid sequence as indicated in the sequence table SEQ. ID. No. 1. It is shown through tests that the antibody prepared through the method is good in reactivity and specificity; due to the fact that a TLR4 gene is a member of a significant pattern recognition receptor Toll-like receptor family targeted to innate immune response, the porcine TLR4 polyclonal antibody can be applied to detection of the porcine TLR4 protein and related research; a good foundation is laid for researching the interaction mechanism between porcine bacterial and viral infection diseases and TLR4 and the virus immunity escape mechanism, and a new target is provided for developing new generation vaccine and medicine. Meanwhile, a prokaryotic expression vector constructed through the method is high in recombinant protein expression efficiency, and the separation and purification method is simple and easy to operate.

The invention relates to a synthetic bifunctional non-antibody compound comprising one or more effector moieties and one or more binder moieties, wherein the effector moieties are operably linked to the binder moieties via a linker, the effector moieties are ligands to at least one pathogen pattern recognition receptor (PRR) and the binder moieties bind to a marker of a tumor cell.

The invention discloses application of a pattern recognition receptor TREM2 in liver cancer prognosis and treatment, and particularly discloses a biomarker used for predicting liver cancer existence and relapse for patients affected with liver cancer, and application of the TREM2 as a novel target in liver cancer targeted treatment. Researches show that expression of the TREM2 is obviously reducedin liver cancer tissue, and is significantly lower than that in normal tissue; low expression of the TREM2 in liver cancer tissue is closely related to poor prognosis of patients; the total survivaltime and the tumor progression time of a patient with low TREM2 expression are shorter than those of patients with high expression; and after activation and overexpression of the TREM2 in MHCC97H cells, proliferation capability of liver cancer cells is significantly suppressed. Accordingly, the TREM2 can be adopted as the biomarker for prognosis of patients with liver cancer, and can predict the survival time of patients with liver cancer and the risk of relapse, and the TREM2 can be adopted as a novel treatment target to perform individualized precise intervention treatment according to the level of the receptor TREM2 of patients.

Compositions and methods are contemplated for treatment of a wound, and especially a sterile or TLR / NOD ligand-poor wound in which contemporaneous administration of a Ca2+-flux agonist (CFA) and a pattern recognition receptor (PRR) ligand improves wound healing.

The invention discloses an immune cell containing a tumor antigen recognition receptor and application of the immune cell. The immune cell containing the tumor antigen recognition receptor expresses hyaluronidase, wherein the hyaluronidase comprises: a) a full-length protein anchored to the immune cell; or b) a soluble protein secreted to the outside of the immune cell. The invention also discloses application of the immune cell in preparation of drugs for treating tumors. According to the immune cell containing the tumor antigen recognition receptor, an effect of normalizing a tumor immune microenvironment by changing the extracellular matrix structure of the microenvironment can be changed, so that the immune cell can effectively approach and kill tumor cells. With the help of the soluble PH20 protein, the immune cell containing the tumor antigen recognition receptor can also improve the tumor microenvironment and effectively kill the tumor cells.

The present invention discloses cationic nucleic acid scavengers to effectively inhibit the activation of multiple nucleic acid sensing pattern recognition receptors (PRRs) to treat an inflammatory orimmune response which is induced by a nucleic acid through the activation of the PRRs. The cationic nucleic acid scavengers include water soluble cationic polymers, cationic nanoparticles, and cationic micro-particles, and bind the nucleic acid in a manner that is independent of the sequences, structure or chemistry of the nucleic acid.

Disclosed are compounds and compositions for the activation or induction of expression of a pattern recognition receptor (e.g., STING, RIG-I, MDA5), and methods of use thereof.

The invention relates to application of TLR3 in predicting tumor transfer, evaluating prognosis and selecting prevention and treatment schemes. The invention particularly relates to application of a substance for detecting a pattern recognition receptor TLR3 in a biological sample in preparing products for predicting tumor transfer in the object and / or evaluating object tumor prognosis and / or selecting tumor prevention and treatment schemes, and a corresponding product and method thereof. The invention provides application of the pattern recognition receptor TLR3 in predicting tumor transfer, evaluating prognosis and selecting prevention and treatment schemes, also provides a corresponding product and method, and has certain clinical application prospects.

The invention discloses a novel shellfish pattern recognition receptor LRPP (Leucine-rich Repeat Protein) specifically combined with LPS (Lipopolysaccharide). The amino acid sequence of the shellfish pattern recognition receptor LRPP is as shown in SEQ ID NO.2. The LRPP is separated from crassostrea gigas for the first time, LPS can be specifically recognized, and the novel shellfish pattern recognition receptor LRPP can trigger later immunoreaction. The LRRP disclosed by the invention plays an important role in shellfish immunological recognition, can monitor the invasion situation of intracorporal gram-negative bacteria, and provides significant theory and practice basis for anti-disease breeding of shellfish.

The invention provides a nanoparticle carrier CaP / PEI / poly(I:C) / SiO2-SH containing a TLR3 ligand in PRRs (pattern recognition receptors). The compound is characterized in that calcium phosphate nanoparticles are taken as a core, the surface of the core is grafted with PEI, Poly(I:C) is adsorbed and supported on the surface of the core, a SiO2 shell is located outside the core, and under the actionof trimethoxysilane, the SiO2 shell can carry thio groups to be functionalized and can carry different fluorescent dyes such as FITC, Cy5 and the like. Further, the invention provides a preparation method and a medical application of the compound. Nanoparticles are stable in property and lower in cytotoxicity and can carry different fluorescent dyes, binding of poly(I:C) and TLR3 can be realizedeffectively with the nanoparticles as the carrier, production of interferons and proinflammatory factors is enhanced by activating a TLR3 mediated signaling pathway, and the nanoparticles are expectedto be used as drug in-vivo imaging tools and vaccine carriers.

Disclosed are compounds and compositions for the activation or induction of expression of a pattern recognition receptor (e.g., STING, RIG-I, MDA5), and methods of use thereof.

Improved assays for detecting the presence of a specific cell-mediated immune response in an individual are provided, where a sample comprising T cells and other cells of the immune system, usually a blood sample or derivative thereof, is contacted with test antigen(s) of interest in the presence of a pattern recognition receptor (PRR) agonist. The sample is incubated for a period of time sufficient to activate effector T cells; and release of immune effector molecule(s) is then detected. In some embodiments, the PRR is an agonist of a toll-like receptor (TLR) expressed by mature antigen presenting cells, including without limitation agonists TLR3 and TLR7, such as LPS, poly I:C, imiquimod, etc.

The present invention encompasses methods and kits employing pattern recognition receptor expression as a measure of systemic health in a subject afflicted with an oral health condition. In particular, the present invention is directed to methods involving measurement of the expression levels of one or more Pattern Recognition Receptors including but not limited to Toll Like Receptors, myeloid differentiation primary response gene 88 (MyD88), and Nucleotide Binding oligomerization domain containing protein 1 (NOD1), in a companion animal, e.g., a dog or a cat, afflicted with an oral health condition. The described methods enable evaluation of the systemic health of the animal afflicted with an oral health condition by measuring expression levels of the indicated genes as compared to suitable controls.

The invention discloses a recombinant bacterium targeted to silence a plutella xylostella GNBP2 gene and application thereof in pest control. Specifically, the nucleotide sequence of plutella xylostella pattern recognition receptor protein gene GNBP2 is shown in SEQ ID NO:1; the amino acid sequence of the plutella xylostella pattern recognition receptor protein GNBP2 is shown in SEQ ID NO:2. According to the recombinant bacterium, it is found for the first time that a pest immune system is the negative bacteria-binding protein GNBP2 gene in a target system, the expression of the gram-negativebacteria-binding protein GNBP2 and downstream antibacterial peptide gene can be effectively reduced, and the sensibility of the plutella xylostella to the gram-negative bacteria, gram-positive bacteria, and fungi is greatly improved, and the mortality is further increased. According to the recombinant bacterium, a theoretical foundation is laid for the development of human and livestock safe immunosuppressants, a novel theory is provided for the biological control of pests, and novel strategies and novel approaches of pest control are provided for green agricultural production and sustainabledevelopment in China.

The invention relates to the field of biotechnology and medical diagnosis. According to the invention, molecule-pattern recognition receptors RIG-I with tumor expression correlation and having regulation effect on the growth of cancer cells are screened out from gene chip. The invention further provides application of the pattern recognition receptors RIG-I in preparation of anticancer drugs; the application specifically refers to combination between the pattern recognition receptors RIG-I and interferon alpha. The invention provides a new idea for oncotherapy.

The present invention refers to a method for recognizing and / or characterizing cellular activity patterns, in particular for diagnostic purposes and / or for tracking the therapy of diseases. Blood cells are stimulated in a culture medium at least with toll-like receptor ligands (TLR ligands) and the stimulated blood cells and / or the culture medium are examined.

The present invention relates, in general, to pattern-recognition receptors (PRRs), including toll-like receptors (TLRs), and, in particular, to a method of inhibiting nucleic acid-induced activation of, for example, endosomal TLRs using an agent that binds to the nucleic acid (“nucleic acid binding agent”), preferably, in a manner that is independent of the nucleotide sequence, the chemistry (e.g., DNA or RNA, with or without base or sugar modifications) and / or the structure (e.g., double-stranded or single-stranded, complexed or uncomplexed with, for example protein) of the nucleic acid(s) responsible for inducing TLR activation. The invention also relates to methods of identifying nucleic acid binding agents suitable for use in such methods.

The invention discloses a cDNA full-length sequence of a paralichthys olivaceus mode recognition receptor TLR8 and a clone and detection method. The sequence has 3614 bp in total length, an open reading frame containing 3078 bp and codes 1024 amino acid. According to the cds sequence conserved region design and a primer of the proximal species TLR8, by means of inverse transcription and PCR amplification, under the combination of the RACE technique, the full-length cDNA sequence of the paralichthys olivaceus TLR8 is obtained. The TLRs family is a main 'pattern recognition receptor' for animals to identity and invade pathogens, and by sensing and identifying the relative molecular pattern of the pathogens, the natural immune system is activated. The acquisition of the gene sets a foundation for researching the gene expression regulation mechanism and immunologic functions of the fish TLR8, and molecular materials are provided for researching fish population genetics and evolutionary genetics.